MYC and acute myeloid leukemia: The genetic landscape of BPDCN is now well-defined (MYC/MYC rearrangements, epigenetic defects, oncogenic and immune pathways), while pDC-AML now appear to exhibit an original mutation landscape, which is of interest for diagnostic criteria.